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PURPOSE. Pathologic corneal neovascularization is a major cause of blindness worldwide, and
treatment options are currently limited. VEGF is one of the critical mediators of corneal
neovascularization but current anti-VEGF therapies have produced limited results in the
cornea. Thus, additional therapeutic agents are needed to enhance the antiangiogenic arsenal.
Our group previously demonstrated epithelial membrane protein-2 (EMP2) involvement in
pathologic angiogenesis in multiple cancer models including breast cancer and glioblastoma.
In this paper, we investigate the efficacy of anti-EMP2 immunotherapy in the prevention of
corneal neovascularization.
METHODS. An in vivo murine cornea alkali burn model was used to study pathologic
neovascularization. A unilateral corneal burn was induced using NaOH, and subconjunctival
injection of either anti-EMP2 antibody, control antibody, or sterile saline was performed after
corneal burn. Neovascularization was clinically scored at 7 days postalkali burn, and eyes
were enucleated for histologic analysis and immunostaining including VEGF, CD31, and CD34
expression.
RESULTS. Anti-EMP2 antibody, compared to control antibody or vehicle, significantly reduced
neovascularization as measured by clinical score and central cornea thickness, as well as by
histologic reduction of neovascularization, decreased CD34 staining, and decreased CD31
staining. Incubation of corneal limbal cells in vitro with anti-EMP2 blocking antibody
significantly decreased EMP2 expression, VEGF expression and secretion, and cell migration.
CONCLUSIONS. This work demonstrates the effectiveness of EMP2 as a novel target in pathologic
corneal neovascularization in an animal model and supports additional investigation into
EMP2 antibody blockade as a potential new therapeutic option.
Keywords: cornea, corneal neovascularization, epithelial membrane protein-2, vascular
endothelial growth factor, angiogenesis
The cornea is a transparent tissue that plays a critical role inlight refraction and vision. As it is in physical contact with
the external environment, the cornea also acts as a mechanical
barrier to provide protection against microorganisms, toxi-
cants, and injury. Under normal conditions, the cornea is clear
and has several antiangiogenic factors including soluble VEGF-
R1 which helps maintain its unique avascular status.1 However,
pathologic neovascularization can occur secondary to trauma,
chemical burns, immunologic disease, or infection,2 leading to
an upregulation of proangiogenic factors including VEGF-A that
promotes hemangiogenesis and inflammation.3 Corneal neo-
vascularization typically presents as ingrowth of blood vessels
from the limbus toward the clear center of the cornea. The
resulting abnormal blood vessel growth, corneal opacity, and
corneal edema reduces the transparency of the cornea, which
is critical for good visual acuity.4 As such, neovascularization
remains a major cause of blindness worldwide. As many as 1.4
million Americans are seen by physicians each year for vision
impairment secondary to abnormal blood vessel growth,5,6 and
these causes of corneal blindness present a pressing challenge
to address.
Treatment options for corneal neovascularization are
limited. Steroids and anti-inflammatory drugs are currently
used, but efficacy can be variable and these drugs can
produce significant side effects when chronically adminis-
tered.2 Biologic agents, including intravitreal injections of
anti-VEGF antibodies, are increasingly being used to treat a
wide variety of ocular diseases involving abnormal retinal
neovascularization, including age-related macular degenera-
tion, diabetic retinopathy, and retinopathy of prematurity.
Given the clinical efficacy of anti-VEGF in the treatment of
these retinal diseases, some studies support efficacy in
reducing corneal neovascularization in both animal models
and clinical trials.7–9 These anti-VEGF agents have shown
initial therapeutic success with at least partial reduction of
corneal neovascularization through topical, subconjunctival,
and intraocular application.10–14 Although these results are
encouraging, anti-VEGF biologics have been associated with
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significant systemic toxicity and severe ocular complica-
tions,15 and additional therapeutics to complement these
drugs would be advantageous.
Our lab has extensively studied the role of EMP2, a
membrane bound tetraspan protein, in multiple models of
vascular development. Prior studies demonstrated a role for
EMP2 in pathologic angiogenesis in breast cancer,16 endome-
trial cancer,17–20 glioblastoma,21–23 and placental angiogene-
sis.24 EMP2 mRNA is expressed at high levels in the eye, lung,
and uterus.25 In the eye, EMP2 is localized to the epithelial
layers of the cornea, ciliary body, RPE-choroid, and stromal
layers of the sclera.26 Within the retina, EMP2 is found on the
membrane of the RPE, and appears to contribute to the
pathogenesis observed in proliferative vitreoretinopathy.27–30
EMP2 controls VEGF expression in the RPE cell line ARPE-19.31
Given the protein’s role in development of vasculature in
multiple disease contexts, and its expression in several discrete
subanatomic locations in the eye including corneal epithelium,
we sought to investigate its involvement in pathologic
neovascularization of the cornea. In this paper, we characterize
the expression of EMP2 in the human cornea and localize it to
the corneal epithelium. Moreover, we show that EMP2
contributes to corneal neovascularization in a murine corneal
burn model in vivo and VEGF expression in vitro in a corneal
limbal derived cell line.
MATERIALS AND METHODS
Animals
We obtained 6- to 8-week-old female Balb/c mice from Jackson
Laboratories (Bar Harbor, ME, USA), and housed at the
University of California, Los Angeles, in the Division of
Laboratory Animal Medicine facility. All animal experiments
were reviewed and approved by the University of California,
Los Angeles, Chancellor’s Animal Research Committee, in
adherence to the Association for Research in Vision and
Ophthalmology Statement for the Use of Animals in Ophthal-
mic and Vision Research.
Corneal Neovascularization Induction and
Treatment
Corneal neovascularization was induced in 6- to 8-week-old
female Balb/c mice using an alkali burn method.32 Animals
were anesthetized with 100 lL of ketamine (50 mg/kg) and
xylazine (5 mg/kg) solution delivered via intraperitoneal
route. The right eye (OD) of each animal was exposed to a 2-
mm diameter filter paper soaked with sterile 1 M NaOH for
45 seconds, filter paper was removed using sterile forceps,
and the eye was immediately rinsed twice with 10 mL of
sterile saline. The left eye (OS) of each animal remained
unburned as an untreated internal control. Following the
alkali burn, the animals were treated once with either saline,
175 lg of control antibody (human IgG antibody, Sigma-
Aldrich Corp., St. Louis, MO, USA), or 175 lg of human anti-
EMP2 antibody (purified humanized monoclonal IgG1) via
one subconjunctival injection in the temporal region of the
conjunctiva. A total of eight mice were used per treatment
group. We administered 100 lL of buprenorphine (0.1 mg/
kg) via subcutaneous route in the shoulder area prior to alkali
burn to aid with pain management. Erythromycin ointment
was applied daily for 3 days and monitored daily. The
experiment was terminated using euthanasia at day 7
postburn and both eyes were enucleated for additional
evaluation.
Clinical Vascular Evaluation
Assessment of corneal neovascularization was performed in a
masked fashion using a surgical microscope (Leica S6D; Leica
Microsystems; Buffalo Grove, IL, USA). Neovascularization
scoring was based on a scale of 0 to 3, as previously
described32 at 7 days post-alkali burn, and prior to enucle-
ation.
Areas of neovascularization in the corneas exposed to
alkali burn were traced using the Simple Neurite Tracer
plugin via NIH ImageJ software33 (http://imagej.nih.gov/ij/;
provided in the public domain by the National Institutes of
Health, Bethesda, MD, USA). Images were automatically
converted to 32-bit grayscale images by the Simple Neurite
Tracer plugin.
Cell Culture
Human corneal limbal epithelial (HCLE; HCLE cells were
provided by Ilene Gipson, PhD, at Schepens Eye Research
Institute, Harvard Medical School) cells were cultured using 1X
keratinocyte serum-free medium, per manufacturer’s formula-
tion (Thermo Fisher Scientific, Waltham, MA, USA) at 378C, in a
humidified 5% CO2 incubator. HCLE cells were grown to 80%
confluency and exposed to 60 lg/mL of anti-EMP2 antibody for
6, 12, 24, or 48 hours. Human umbilical vein endothelial cells
(HUVEC; ATCC, Manassas, VA, USA) were cultured in VEC
MCDB-131 complete media (VEC Technologies, Rensselaer, NY,
USA) at 378C in a humidified 5% CO2 incubator. HUVECs for in
vitro assays were used at passage number 3.
Western Blot Analysis
Cell lysates were prepared and lysed in Laemmli buffer.
Proteins were separated on 4% to 20% SDS-PAGE gel (Thermo
Fisher Scientific) under reducing conditions, transferred to
nitrocellulose membranes (GE Healthcare, Chicago, IL, USA),
and blocked with 10% nonfat dry milk in Tris-buffered saline
with 0.1% Tween 20. Membranes were probed with the
following primary antibodies: anti-VEGF (1 lg/mL; Santa Cruz
Biotechnology, Dallas, TX, USA); anti-EMP2 (1:2000; polyclonal
antibody; created in our lab and previously published26); anti-b-
actin (0.5 lg/mL; US Biological, Salem, MA, USA). Protein
bands were detected using horseradish peroxidase (HRP)-
labeled secondary antibodies (Southern Biotechnology, Bir-
mingham, AL, USA), followed by chemiluminescence (ECL;
EMD Millipore, Burlington, MA, USA). Densitometric analysis of
the protein bands were performed using NIH ImageJ software.
Loading variability between samples were normalized to b-
actin loading controls. At least three independent experiments
were performed, and statistical significance was evaluated
using Student’s t-test.
ELISA
Conditioned media were collected from HCLE cells incubat-
ed with media only, or with 60 lg/mL of anti-EMP2 antibody
for 6, 12, 24, or 48 hours. Secreted VEGF from conditioned
media was detected and analyzed per manufacturer’s
instructions (Human VEGF Quantikine ELISA kit; R&D
Systems, Minneapolis, MN, USA). Each condition was assayed
in duplicate and VEGF standards were provided by the
manufacturer for quantitation. Optical density was deter-
mined using a microplate reader (SpectraMax; Molecular
Devices, Sunnyvale, CA, USA) at 540 and 450 nm. Wavelength
correction was performed to correct for optical imperfec-
tions in the plate. At least three independent experiments
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were performed, and statistical significance was evaluated
using Student’s t-test.
Cell Migration Assay
HUVECs were seeded into the upper compartment of transwell
inserts of Boyden chambers (24-well plate; Corning, Corning,
NY, USA). Conditioned media from HCLE cells were prepared
as described above. Bevacizumab (Avastin; Genentech Bio-
Oncology, San Francisco, CA, USA) at 60 lg/mL was added to
untreated HCLE media as a negative control for the migration
assay. We added 500 lL of HCLE conditioned media into the
lower compartment of the Boyden chamber. After 5 hours of
incubation at 378C in a humidified 5% CO2 incubator with the
conditioned media, the transwell inserts were fixed with 4%
paraformaldehyde and stained with 0.2% crystal violet. The
inserts were carefully washed with distilled water and left to
dry overnight at room temperature. The inserts were imaged
and the migrated cells were quantified to determine number of
migrated HUVEC cells. At least three independent experiments
were performed, and statistical significance was evaluated
using Student’s t-test.
Immunostaining and Immunofluorescent
Microscopy
We fixed 5 lm OCT frozen sections from unfixed human
corneal limbus samples (gift from Sophie Deng, MD, PhD, Stein
Eye Institute, University of California, Los Angeles, CA, USA)
were fixed with 4% paraformaldehyde for 10 minutes, blocked
with 1% normal goat serum for 1 hour, and incubated
overnight at 48C with anti-EMP2 (1:1500; polyclonal antibody).
Visualization of the immunostaining was performed using an
anti-rabbit kit (IgG ABC Vector kit; Vector Laboratories,
Burlingame, CA, USA), according to manufacturer’s instruc-
tions. Alcian blue/methyl green counterstain was used, and
slides were mounted for brightfield microscopy (BX51;
Olympus, Waltham, MA, USA).
HCLE cells were cultured on glass cover slips for 24 to 48
hours at 378C, in a humidified 5% CO2 incubator. Cells were
fixed with 4% paraformaldehyde for 10 minutes, and stained
with primary antibody, anti-EMP2 (1:500; polyclonal antibody)
overnight at 48C. Goat anti-rabbit IgG AlexaFluor 594 (2 lg/mL;
Thermo Fisher Scientific) was used for secondary detection.
Coverslips were counterstained with DAPI and mounted.
Images were obtained at 3400 magnification by immunofluo-
rescence microscopy (Olympus).
Unburned and alkali-burned eyes were enucleated, forma-
lin-fixed, and sectioned at 4 lm. Some sections were stained
using hematoxylin and eosin (H&E). Additional sections were
deparaffinized and incubated at 958C for 25 minutes in 0.1 M
citrate, pH 6.0, for antigen retrieval and use in immunohis-
tochemical studies. The following primary antibodies were
used: anti-CD34 (5 lg/mL; Abcam, Cambridge, MA, USA),
anti-CD31 (10 lg/mL; Dianova, Hamburg, Germany), anti-
LYVE-1 (0.2 lg/mL; R&D Systems) and anti-VEGF (4 lg/mL,
clone A-20; Santa Cruz Biotechnology). Detection of the
immunostaining was executed using anti-rat IgG and anti-
rabbit kit (Vector Laboratories), according to manufacturer’s
instructions. Sections were counterstained and mounted.
Detection of bound anti-CD31 or the anti-LYVE-1 antibodies
was performed using anti-rat IgG AlexaFluor 594 and anti-
goat IgG AlexaFluor 594 (Thermo Fisher Scientific) and
immunofluorescent evaluation. Sections were counterstained
with DAPI, and mounted with Prolong (Thermo Fisher
Scientific). Images were obtained at 3400 magnification by
brightfield microscopy (Olympus). NIH ImageJ software was
used to quantitate CD31 and LYVE-1 fluorescent staining.
Images were converted to 8-bit grayscale images and
positively stained areas were quantitated.
RESULTS
EMP2 is Expressed in Human Corneal Epithelium
and HCLE Cells
Sections of human cornea were stained for EMP2 expression to
confirm EMP2 localization in human cornea. EMP2 was
strongly expressed in corneal epithelium (Fig. 1A). EMP2
expression was also independently confirmed in human
corneal-limbal epithelial (HCLE) cells, a frequently used
immortalized human corneal epithelial cell line (Fig. 1B). The
HCLE cells demonstrated strong punctate staining of EMP2,
which interestingly appeared to be localized to sites of direct
cell-cell contact, as observed in other cell types.28,36,37
We next sought to explore whether EMP2 expression plays
a pathologic role in a murine model of aberrant corneal
neovascularization. To study corneal neovascularization, we
utilized an in vivo murine corneal burn model as described in
the methods section.32
Blockade of EMP2 Results in Clinically Decreased
Corneal Neovascularization in an In Vivo Mouse
Burn Model
Alkali burn resulted in significant opacification and neovas-
cularization of the cornea in all burned eyes compared to
internal unburned control (data not shown). No cases of
corneal perforations or infections were observed at any point
in these studies. All eyes were used in subsequent analyses.
Surgical microscopy images at 7 days postcorneal burn
showed significantly less neovascularization in the anti-
EMP2 treated eyes compared to saline control and control
antibody treated eyes (Fig. 2). Vasculature was manually
traced to highlight the degree of neovascularization (Fig. 2A,
lower panel). A clinical scoring protocol was used to
quantitate neovascularization based on a previously published
clinical assessment protocol.32 Corneal neovascularization
was clinically scored by masked observers using day 7 corneal
images comparing burned eye with internal control eye, with
0¼no neovascularization; 1¼minor neovascularization at the
corneal limbus; 2 ¼ moderate neovascularization at the
corneal limbus with few vessels approaching corneal center;
3 ¼ extensive neovascularization at the corneal limbus and
moderate to many vessels spanning the corneal center.32 The
mean clinical neovascularization score from 8 animals per
group revealed significantly less corneal neovascularization in
the anti-EMP2 antibody treated group compared to controls
(Fig. 2B).
Anti-EMP2–Treated Animals Have Reduced Central
Cornea Thickness and Decreased CD34, VEGF, and
CD31 Staining in Cornea
The foregoing results suggested that antibody-targeting of
EMP2, when given at the time of injury, decreased develop-
ment of pathologic corneal neovascularization. To further
characterize this finding, alkali burned eyes from the anti-
EMP2 antibody, control antibody, and saline groups were
further compared histologically and immunohistochemically
for the markers CD34, VEGF, and CD31 (Fig. 3A). Notably,
anti-EMP2–treated corneas have significantly reduced corneal
thickness as compared to saline treated eyes (Fig. 3B). This
may be clinically important because corneal edema indepen-
dently contributes to loss of visual acuity even in the absence
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of neovascularization, as in the case of a variety of diseases
involving corneal endothelial dysfunction.34 Burned eyes
demonstrate reduced thickness of the corneal epithelial layer,
however when all of the eyes were evaluated the average
epithelial thickness is unchanged regardless of treatment (Fig.
3C). Expression of CD34, a marker for hematopoietic
progenitor cells35 and a probe for neovascularization in
multiple tumor models,17,36 was identified using immunohis-
tochemistry. Corneas from animals that received anti-EMP2
antibody showed significantly decreased CD34 staining
compared to controls (Fig. 3A, second row), quantified by
immunohistologic staining intensity (Fig. 3D). CD34 staining
was more strongly observed in the corneal epithelium and the
areas adjacent to the corneal endothelium with minimal
expression in the corneal stroma. Little to no CD34
expression is observed in control unburned corneas. Expres-
sion of an endothelial cell specific marker, CD31, was also
used as an independent validation to detect neovasculariza-
tion, via immunofluorescent staining (Fig. 3A, bottom row).
Quantitation of positively stained CD31 areas of immunoflu-
orescent staining, showed that anti-EMP2 antibody signifi-
cantly decreased CD31 staining compared to vehicle and IgG
controls (Fig. 3E). Corneal staining with CD34 and CD31 were
concordant, in that anti-EMP2 antibody treated animals
showed reduced neovascularization compared to control
groups. Anti-EMP2–treated eyes also showed a similar
reduction in VEGF expression compared to saline and control
antibody treated eyes (Fig. 3A, third row), with minimal to no
expression of VEGF in anti-EMP2 antibody treated eyes.
Additional staining using a marker for lymphatics (LYVE-1)
was used and did not show significant staining in the central
cornea under any of the tested conditions (Supplementary
Fig. 1A, top panel). LYVE-1 staining was observed in the
peripheral cornea of all 3 tested conditions (Supplementary
Fig. 1A, bottom panel); however, upon quantitation of the
stained areas, no significant differences across the three
groups were observed (Supplementary Fig. 1B). We proceed-
ed to further characterize the relationship between EMP2 and
VEGF in vitro.
Incubation With Anti-EMP2 Antibody Results in
Decreased EMP2 Expression and Decreased VEGF
Expression In Vitro in HCLE Cells
Our lab had previously demonstrated that EMP2 controls
VEGF expression in the retinal cell line ARPE-19.31 To
FIGURE 1. EMP2 is expressed in human corneal epithelium and HCLE cells. (A) Sections of human cornea were stained via immunohistochemistry
for EMP2 expression using a polyclonal anti-human EMP2 antibody. EMP2 was noted to be expressed in the corneal epithelium. Scale bar: 200 lm.
(B) HCLE cells demonstrated strong punctate staining of EMP2. Notably, EMP2 was only expressed in cells with direct cell-cell contact. Phase
contrast, EMP2 staining (red), and merged images shown. Scale bar: 50 lm.
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investigate the relationship between EMP2 expression and
VEGF expression in cells derived from the corneal epithelium,
we used the human HCLE cell line exposed to anti-EMP2
antibody and quantified expression of EMP2 and VEGF by
western blot (Fig. 4A). Anti-EMP2 treatment appears to
decrease both EMP2 and VEGF expression in a time-
dependent fashion. Expression of EMP2 protein reached a
nadir after 12 to 24 hours of anti-EMP2 blockade (Fig. 4B),
while expression of VEGF reached a nadir at 12 hours of anti-
EMP2 blockade (Fig. 4C). This demonstrated that the
expression of EMP2 and VEGF is correlated, and both can
be downregulated in a time-dependent fashion by EMP2
antibody blockade.
Supernatants From HCLE Cells Previously
Incubated With Anti-EMP2 Antibody Show
Reduction in Secreted VEGF and Reduced Cell
Migration in a Transwell Migration Assay
Supernatants from HCLE cells treated with EMP2 antibody
were further tested for presence of secreted VEGF and its
functional capacity in a transwell migration assay. Secreted
VEGF-A was directly measured by ELISA and demonstrated a
time-dependent reduction in VEGF secretion with EMP2
blockade (Fig. 5A). The supernatants were also used to test
function in an HUVEC transwell migration assay. Notably, there
is a statistically significant reduction in number of cells
migrated at 12 and 24 hours using supernatants from HCLE
cells exposed to EMP2 blockade (Fig. 5B). This reduced cell
migration is likely secondary to reduction in secreted growth
factors including VEGF following exposure to the anti-EMP2
antibody.
DISCUSSION
In this paper, an interaction between EMP2 and VEGF in the
murine alkali burn model of corneal neovascularization is
demonstrated, which is concordant to other studies that link
EMP2 to control of VEGF in tumor models and in the retinal
epithelial cell line ARPE-19.17,22,29,31 EMP2 blockade using anti-
EMP2 antibodies reduce pathologic neovascularization and
corneal edema following corneal burn. This suggests EMP2 as a
potentially new target for prevention of corneal neovascular-
ization.
In corneal epithelium and model HCLE cells, we observed
that EMP2 was localized to sites of direct cell-cell contact.
EMP2 is a member of the GAS-3 protein family, whose cell
biology includes interaction with integrins37 and caveolin-
1,38 mediation of protein trafficking including MHC class I to
lipid raft microdomains,39 a role in apical membrane
recycling, and in cell-cell and cell-extracellular matrix
interactions.26 These biologic precedents are consistent with
localization of EMP2 in sites of cell-cell contact in corneal
epithelium, and suggest an analogous functional cell biology
in this cell type.
In normal and neoplastic cell types, EMP2 previously has
been shown to promote autonomous VEGF expression, a
phenotype that could be reversed by molecular inhibition of
EMP2 expression or antibody blockade with anti-EMP2
antibody.17,22,29,31 These precedents, and EMP2 expression
in corneal epithelium, formed the rationale for testing
whether EMP2 blockade could block corneal neovascular-
ization.
We demonstrated that blocking EMP2 signaling results in a
time dependent decrease in EMP2 expression as well as VEGF
expression. Our experiments showed that after anti-EMP2
blockade, expression of EMP2 protein reached a nadir after 12
FIGURE 2. Blockade of EMP2 results in clinically decreased corneal neovascularization in an in vivo mouse burn model. (A) Surgical microscopy
images at 7 days postalkali burn and antibody treatment reveal corneal opacity and corneal neovascularization across all three groups of animals.
Less corneal neovascularization is observed in anti-EMP2 antibody–treated eyes, when compared to saline and control antibody treated animals.
Vasculature was manually traced using ImageJ to emphasize degree of neovascularization. (B) The mean clinical neovascularization score from eight
animals per group shows that control antibody treated animals have more corneal neovascularization than the anti-EMP2 antibody–treated group (*P
< 0.05).
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FIGURE 3. Anti-EMP2–treated animals have reduced central cornea thickness and decreased CD34, VEGF, and CD31 staining in cornea. ([A], top
row) H&E-stained sections were obtained, and the average of three measurements in the central region of each burned cornea were taken. ([A],
second row) Immunohistochemical staining of CD34 expression in the treated and untreated corneas show an increase in CD34-positive staining in
the saline and control antibody–treated animals, with markedly reduced CD34 staining in anti-EMP2 treated animals. Little to no CD34 expression is
observed in the control unburned cornea. (A, third row) Immunohistochemical staining of VEGF expression shows a similar increase in VEGF
expression of saline and control antibody treated animals, with markedly reduced VEGF staining in anti-EMP2 treated animals. (A, bottom row)
Staining via immunofluorescence with anti-CD31, an endothelial cell specific marker, shows increased expression, as predicted, in the control burns
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to 24 hours. Correspondingly, VEGF secretion was decreased
between 6 and 24 hours, with a nadir around 12 hours. This is
consistent with our hypothesis that VEGF expression decreases
in response to an EMP2 decrease, with the caveat that use of
the anti-EMP2 blocking antibody does not characterize the
relative production of EMP2 and VEGF protein in a time
dependent manner. However, previous experiments have
shown that siRNA knock-down of EMP2 reduces total VEGF
expression by 57%, and conversely EMP2 overexpression
increased VEGF expression by 1.5-fold.31
The expression of the growth factor VEGF is complex and
regulated by many factors at the transcription, translation, and
secretion levels. Rapid release is possible due to preexisting
pools of protein regulated at the secretion level, with inducible
secretion seen as rapidly as within 30 min in human vascular
smooth muscle cells, platelets, and neutrophils,40 as well as
neuroblastoma tumor cells.41 Additionally, certain ocular cell
models (retinal pigment epithelium/choroid in ex vivo organ
culture42 and the human retinal pigment epithelium cell line
ARPE-1943) constitutively express and secrete VEGF, with their
constitutive secretion further modifiable by external factors.
Furthermore, low levels of constitutive expression of VEGF-A
has also been reported in human corneal epithelial cells and
human corneal stromal fibroblasts,44 corroborating evidence
here that VEGF and EMP2 play integral roles in the corneal
vascular state.
Anti-VEGF antibody therapy is an FDA approved and
clinically successful treatment for multiple conditions involv-
ing abnormal angiogenesis, including retinal neovasculariza-
tion.45 Several direct VEGF pathway inhibitors are currently
FDA approved, including various classes of biologicals and
orally available small molecule downstream tyrosine kinase
inhibitors.46–49 In addition to therapeutic efficacy in several
human cancers,50 anti-VEGF immunotherapy has an estab-
lished role in ophthalmology,51 including age-related macular
degeneration52,53 and proliferative diabetic retinopathy.54
Additionally, anti-VEGF therapy has evidence of efficacy in
other neovascular diseases, including diabetic macular ede-
ma,55,56 neovascular glaucoma,57 branch retinal vein occlusion,
and central retinal vein occlusion,58–60 iris neovasculariza-
tion,61 and retinopathy of prematurity.62–65
However, adverse events may occur as a clinical factor in
therapeutic VEGF inhibition. This includes systemic vascular
toxicity such as arterial and venous thromboembolic events
and its cardiac complications,66,67 and systemic effects of
intraocular administration in one large meta-analysis68 (al-
though not observed in other studies).69,70 There is also
clinical evidence of local toxicity from VEGF blockade,71,72
including acute and chronic elevated intraocular pressure.73,74
Based on the present findings, anti-EMP2 antibody therapy
might offer a biologically distinct strategy to reduce neovascu-
larization. Moreover, it offers a novel treatment option that may
avoid some of the side effects inherent in anti-VEGF
therapy,15,75 while maintaining its inhibitory effects on
neovascularization and angiogenesis. Similar to some studies
using VEGF antibodies in treatment of corneal neovasculariza-
tion,7,8,14 a minimally invasive subconjunctival injection route
of anti-EMP2 antibody is effective in this model. Anti-EMP2
human monoclonal antibody has already shown promise in
preclinical testing against both breast cancer16 and glioblasto-
ma.21,22 Additionally, polyclonal EMP2 blocking antibodies
have been used with ARPE-19 cells in the successful treatment
of a rabbit model of experimental proliferative vitreoretinop-
FIGURE 4. Incubation with anti-EMP2 antibody results in decreased
EMP2 expression and decreased VEGF expression in vitro in HCLE
cells. (A) HCLE cells were incubated with the anti-EMP2 antibody for
up to 48 hours, and expression of EMP2 and VEGF quantified by
Western blot. (B) Reduction of EMP2 expression decreased to a nadir at
12 to 24 hours, and (C) reduction in VEGF expression reached a nadir
at 12 hours.
(burn þ saline and burn þ control IgG), as compared to the unburned cornea. However, concordant with the CD34 histochemical staining, the
animals who received the burn and anti-EMP2 IgG exhibited reduced new vessel formation as compared with the control burns. (B) The overall
thickness of the central cornea in the anti-EMP2 antibody treated group is significantly reduced compared to the saline treated group (*P < 0.05).
(C) The average of three measurements per eye of epithelial thickness from central cornea were taken. Although all burned eyes have significantly
reduced epithelial thickness compared to unburned control, the overall thickness of the epithelial layer of the cornea is unchanged and unaffected
regardless of type of treatment (saline, control IgG, or anti-EMP2 IgG). (D) Quantitation of CD34 and (E) CD31 positively stained corneal sections
demonstrate similar trends with immunohistochemical and immunofluorescent staining (*P < 0.05). Scale bar: 50 lm.
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athy with no evidence of toxicity to the eye by histology29 or
by electroretinography (Telander D, unpublished observations,
2010). In summary, anti-EMP2 immunotherapy has efficacy in
prevention of corneal neovascularization in the murine burn
model. Additional studies are warranted to explore the
possibility of this target in human ocular neovascular disease.
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